MARKET

VRTX

VRTX

Vertex Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

183.61
-1.48
-0.80%
After Hours: 183.00 -0.61 -0.33% 19:49 09/24 EDT
OPEN
185.30
PREV CLOSE
185.09
HIGH
185.30
LOW
181.98
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
280.99
52 WEEK LOW
181.98
MARKET CAP
47.63B
P/E (TTM)
24.20
1D
5D
1M
3M
1Y
5Y
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
Zacks.com · 23h ago
The Zacks Analyst Blog Highlights: Disney, Adobe, Wells Fargo, IHS Markit and Vertex Pharma
Zacks.com · 1d ago
Zacks Value Investor Highlights: Nu Skin Enterprises, VF Corp, Yamana Gold, Meritor and Vertex Pharmaceuticals
Zacks Value Investor Highlights: Nu Skin Enterprises, VF Corp, Yamana Gold, Meritor and Vertex Pharmaceuticals
Zacks · 1d ago
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Vertex Pharmaceuticals (VRTX) closed at $185.09 in the latest trading session, marking a +0.44% move from the prior day.
Zacks · 1d ago
5 Top Ranked Stocks on Sale Right Now
These stocks are disconnected from their earnings outlook as the analysts remain bullish but the Street is bearish.
Zacks · 1d ago
Is Vertex Pharmaceuticals (VRTX) A Smart Long-Term Buy?
Artisan Partners, a high value-added investment management firm, published its “Artisan Value Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 7.77% was recorded by its Investor Class: ARTLX, 7.81% by its Advi...
Insider Monkey · 1d ago
VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Zacks · 1d ago
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
Zacks.com · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRTX. Analyze the recent business situations of Vertex Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRTX stock price target is 258.59 with a high estimate of 331.00 and a low estimate of 175.00.
EPS
Institutional Holdings
Institutions: 1.27K
Institutional Holdings: 249.85M
% Owned: 96.31%
Shares Outstanding: 259.43M
TypeInstitutionsShares
Increased
382
19.80M
New
110
3.34M
Decreased
331
22.77M
Sold Out
124
1.63M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Executive Director
Jeffrey Leiden
President/Chief Executive Officer/Director
Reshma Kewalramani
Chief Financial Officer/Executive Vice President
Charles Wagner
Chief Operating Officer/Executive Vice President
Stuart Arbuckle
Executive Vice President/Chief Administrative Officer
Michael Parini
Executive Vice President/Chief Scientific Officer
David Altshuler
Executive Vice President
Carmen Bozic
Executive Vice President
Amit Sachdev
Executive Vice President
Bastiano Sanna
Executive Vice President
Ourania Tatsis
Senior Vice President/Chief Accounting Officer
Paul Silva
Lead Director/Independent Director
Bruce Sachs
Independent Director
Sangeeta Bhatia
Independent Director
Lloyd Carney
Independent Director
Alan Garber
Independent Director
Terrence Kearney
Independent Director
Yuchun Lee
Independent Director
Margaret Mcglynn
Independent Director
Diana McKenzie
No Data
About VRTX
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.

Webull offers kinds of Vertex Pharmaceuticals Incorporated stock information, including NASDAQ:VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.